tbuckley/cabot-search huggingface dataset:
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
Authors: Piotr Ponikowski, Bridget-Anne Kirwan, Stefan D Anker, Theresa McDonagh, Maria Dorobantu, Jarosław Drozdz, Vincent Fabien, Gerasimos Filippatos, Udo Michael Göhring, Andre Keren, Irakli Khintibidze, Hans Kragten, Felipe A Martinez, Marco Metra, Davor Milicic, José C Nicolau, Marcus Ohlsson, Alexander Parkhomenko, Domingo A Pascual-Figal, Frank Ruschitzka, David Sim, Hadi Skouri, Peter van der Meer, Basil S Lewis, Josep Comin-Colet, Stephan von Haehling, Alain Cohen-Solal, Nicolas Danchin, Wolfram Doehner, Henry J Dargie, Michael Motro, Javed Butler, Tim Friede, Klaus H Jensen, Stuart Pocock, Ewa A Jankowska, G Azize, A Fernandez, GO Zapata, P Garcia Pacho, A Glenny, F Ferre Pacora, ML Parody, J Bono, C Beltrano, A Hershson, N Vita, HA Luquez, HG Cestari, H Fernandez, A Prado, M Berli, R García Durán, J Thierer, M Diez, L Lobo Marquez, RR Borelli, MÁ Hominal, M Metra, P Ameri, P Agostoni, A Salvioni, L Fattore, E Gronda, S Ghio, F Turrini, M Uguccioni, M Di Biase, M Piepoli, S Savonitto, A Mortara, P Terrosu, A Fucili, G Boriani, P Midi, E Passamonti, F Cosmi, P van der Meer, P Van Bergen, M van de Wetering, NYY Al-Windy, W Tanis, M Meijs, RGEJ Groutars, HKS The, B Kietselaer, HAM van Kesteren, DPW Beelen, J Heymeriks, R Van de Wal, J Schaap, M Emans, P Westendorp, PR Nierop, R Nijmeijer, OC Manintveld, M Dorobantu, DA Darabantiu, D Zdrenghea, DM Toader, L Petrescu, C Militaru, D Crisu, MC Tomescu, G Stanciulescu, A Rodica Dan, LC Iosipescu, DL Serban, J Drozdz, J Szachniewicz, M Bronisz, A Tycińska, B Wozakowska-Kaplon, E Mirek-Bryniarska, M Gruchała, J Nessler, E Straburzyńska-Migaj, K Mizia-Stec, R Szelemej, R Gil, M Gąsior, I Gotsman, M Halabi, M Shochat, M Shechter, V Witzling, R Zukermann, Y Arbel, M Flugelman, T Ben-Gal, V Zvi, W Kinany, JM Weinstein, S Atar, S Goland, D Milicic, D Horvat, S Tušek, M Udovicic, K Šutalo, A Samodol, K Pesek, M Artuković, A Ružić, J Šikić, T McDonagh, J Trevelyan, Y-K Wong, D Gorog, R Ray, S Pettit, S Sharma, A Kabir, H Hamdan, L Tilling, L Baracioli, L Nigro Maia, O Dutra, G Reis, P Pimentel Filho, JF Saraiva, A Kormann, FR dos Santos, L Bodanese, D Almeida, D Precoma, S Rassi, F Costa, S Kabbani, K Abdelbaki, C Abdallah, MS Arnaout, R Azar, S Chaaban, O Raed, G Kiwan, B Hassouna, A Bardaji, J Zamorano, S del Prado, JR Gonzalez Juanatey, FI Ga Bosa Ojeda, M Gomez Bueno, BD Molina, DA Pascual Figal, D Sim, TJ Yeo, SY Loh, D Soon, M Ohlsson, JG Smith, S Gerward, I Khintibidze, Z Lominadze, G Chapidze, N Emukhvari, G Khabeishvili, V Chumburidze, K Paposhvili, T Shaburishvili, G Khabeishvili, O Parhomenko, I Kraiz, O Koval, V Zolotaikina, Y Malynovsky, I Vakaliuk, L Rudenko, V Tseluyko, M Stanislavchuk
Journal: The Lancet (2020)
Abstract 14956: Improved Operative Efficiency for Minimally Invasive Mitral Valve Surgery at a Low-volume Center
Authors: Monica Fowler, Jeffrey B MacLeod, christie aguiar, Alexandra M Yip, zlatko pozeg, Craig D Brown, Jean-François Légaré, Ansar Hassan
Journal: Circulation (2020)

Introduction: When implementing a minimally invasive cardiac surgery program, increased surgical times may serve as a deterrent. Results demonstrating parity in operative times between minimally invasive (MIMVR) and conventional mitral valve replacement/repair (CMVR) have been limited to high-volume centers. The purpose of this study was to examine operative efficiency for MIMVR in a low-volume center. Methods: All patients having undergone non-emergent, isolated MIMVR or CMVR at the New Brunswick Heart Centre from 2011-2017 were considered. Detailed peri-operative data, including cross clamp (XC), cardiopulmonary bypass (CPB), skin-to-skin (SS) and total operative (TO) times, were collected. Patients were assigned to one of 3 eras: 2011-2013, 2014-2015, 2016-2017. Unadjusted comparisons were made between MIMVR and CMVR over the entire study period and within each era. Results: A total of 168 patients were included (MIMVR: 64; CMVR: 104). There was an increase in the number of MIMVR cases over time (2011-2013: 19; 2014-2015: 17; 2016-2017: 28). Patients undergoing MIMVR were less likely to be ≥70years (29.7% vs. 47.1%, p=0.04) and to have had NYHA-IV symptoms (17.2% vs. 41.3%, p=0.002), previous cardiac surgery (4.7% vs. 23.1%, p=0.003) or urgent presentation (12.5% vs. 35.6%, p=0.002). Intra-operatively, MIMVR patients were more likely to have undergone a mitral valve repair (65.1% vs. 29.1%, p&lt;0.0001). No differences were noted in rates of in-hospital mortality (0.0% vs. 5.1%, p=0.29). Median operative times were uniformly longer among MIMVR patients between 2011-2013. However, in 2014-2015 and 2016-2017, these times improved to the point where no significant differences in operative efficiency were noted (Figure). Conclusions: Improved operative efficiency may be safely achieved for MIMVR in a low-volume center. The results of this study should encourage low-volume centers to adopt a minimally invasive approach to isolated mitral valve surgery.
Anxiety, depression, and prognosis after myocardial infarction: Is there a causal association?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Deirdre Lane, Douglas Carroll, Gregory Y.H. Lip
Journal: Journal of the American College of Cardiology (2003)
Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease
Authors: Johanna Strobl, Ram Vinay Pandey, Thomas Krausgruber, Nadine Bayer, Lisa Kleissl, Bärbel Reininger, Pablo Vieyra-Garcia, Peter Wolf, Maaia-Margo Jentus, Margit Mitterbauer, Philipp Wohlfarth, Werner Rabitsch, Georg Stingl, Christoph Bock, Georg Stary
Journal: Science Translational Medicine (2020)

GVHD includes an autoinflammatory host-versus-graft component from recipient-derived skin-resident memory T cells.
Trajectories of asthma and allergies from 7 years to 53 years and associations with lung function and extrapulmonary comorbidity profiles: a prospective cohort study
Authors: Dinh S Bui, Caroline J Lodge, Jennifer L Perret, Adrian Lowe, Garun S Hamilton, Bruce Thompson, Graham Giles, Daniel Tan, Bircan Erbas, Jane Pirkis, Flavia Cicuttini, Raisa Cassim, Gayan Bowatte, Paul Thomas, Judith Garcia-Aymerich, John Hopper, Michael J Abramson, Eugene H Walters, Shyamali C Dharmage
Journal: The Lancet Respiratory Medicine (2020)
Abstract 14102: Prognostic Impact of Peak Systolic Pulmonary Arterial Pressure in Nonagenarians: An Echocardiographic Study
Authors: Shunsuke Shimada, Taku Omori, Goki Uno, Florian Rader, Robert J Siegel, Takahiro Shiota
Journal: Circulation (2020)

Introduction: Recently, a low threshold of estimated peak systolic pulmonary arterial pressure (eSPAP) of 30 mm Hg was reported to be associated with mortality in the general population. However, less is known about the prognostic impact of eSPAP in nonagenarians. Methods: We retrospectively reviewed 596 patients ≥90 years of age referred for echocardiography with a recorded eSPAP and left ventricular ejection fraction ≥50%. eSPAPs were characterized according to their quartile distribution: first quartile (reference group) (&lt;30 mm Hg), second quartile (30-38 mm Hg), third quartile (39-48 mm Hg), fourth quartile (&gt;49 mm Hg). The associations between quartiles of eSPAP and all-cause mortality were tested in Cox models (adjusting for age, sex, body mass index, hypertension, coronary arterial disease, atrial fibrillation, diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease, left-sided valve disease, left atrial area, NYHA class ≥II, left ventricular mass and right ventricular fractional area change). Results: Of the 596 patients, 61% were female, and the median age was 92 years (IQR 91-95). The median eSPAP was 39.0 mm Hg (IQR 30.3-49.0) (Figure). During the median follow-up of 522 days (IQR 59-1337), a total of 268 deaths (45%) occurred. The adjusted risk of mortality in eSPAP 39-48 mm Hg and eSPAP &gt;49 mm Hg were 1.6 and 1.7 times higher than in eSPAP &lt;30 mm Hg, respectively (Table). Conclusions: In conclusion, eSPAP ≥39 mm Hg was independently associated with mortality in nonagenarians. Estimated peak systolic pulmonary arterial pressure could help in prognostic stratification even in oldest-old patients.
Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158
Authors: Tarah J. Ballinger, Guanglong Jiang, Nawal Kassem, Milan Radovich, Bryan P. Schneider
Journal: Clinical Cancer Research (2020)

Abstract Purpose: This retrospective analysis aimed to determine the relationship between body mass index (BMI) and circulating tumor DNA (ctDNA) in triple-negative breast cancer (TNBC), and to evaluate the impact of BMI on disease recurrence and survival in the homogeneous, high-risk population of patients with residual TNBC after neoadjuvant chemotherapy. Experimental Design: BRE12-158 was a phase II trial of genomically directed therapy versus physician’s choice in residual TNBC after chemotherapy. ctDNA was isolated from plasma samples, and categorized as positive or negative. BMI (kg/m2) after surgery was analyzed as both a continuous and categorical variable: normal weight, &amp;lt;25; overweight, 25–30; and obese, ≥30. We compared ctDNA category and BMI, and estimated probability of disease-free survival (DFS), distant DFS (DDFS), and overall survival (OS) by BMI. Results: Of 177 patients in BRE12-158, 172 had BMI and 140 had ctDNA data. There was no difference in mean BMI between those with ctDNA positivity versus negativity (P = 0.48). There was no relationship between BMI category and presence of ctDNA (P = 0.31). In multivariate analysis, continuous BMI was not prognostic of DDFS (P = 0.996), DFS (P = 0.41), or OS (P = 0.98). There was no association between BMI categories and survival (P = 0.92, 0.74, and 0.97 for DDFS, DFS, and OS, respectively). Conclusions: In patients with residual TNBC after neoadjuvant chemotherapy, BMI was not prognostic of DDFS, DFS, or OS. There was no signal of a relationship between BMI and presence of ctDNA. This suggests inherent aggressive tumor biology, in which host phenotype may have less influence and impact of weight loss interventions may be diminished.
Introducing the newly developed SB Knife Jr 2: enhancing creative endoscopic submucosal dissection
Authors: Yasutoshi Shiratori, Takashi Ikeya, Katsuyuki Fukuda
Journal: Endoscopy (2020)

Endoscopic submucosal dissection (ESD) using a scissor-type knife has notable benefits [1] [2] [3] [4] [5]. Its design and rotatability allow increased stability and accurate control of dissection. Additionally, it is useful for accurate vessel sealing and hemostasis. The SB Knife Jr (Sumitomo Bakelite, Tokyo, Japan), developed in 2011, is available worldwide [1]. However, there are some issues related to its use, such as poor repetitive incisional performance, interference with the hood, and cumbersome operation by the assistant. The latest version, the SB Knife Jr 2 (Sumitomo Bakelite), is, like the conventional model, a fully rotatable scissor-type knife with insulated sides to avoid muscular injury, but it also has features addressing the above-mentioned issues, thereby enhancing the safety of ESD. New features of the SB Knife Jr 2 relate to (1) the knife structure, to improve the ability to grasp tissue; (2) the scissor structure, to avoid interference with the hood; (3) the coating of the knife, to improve the repetitive incision ability; and (4) the new rotation operation part ([Fig. 1]). We demonstrate two ESD procedures using the SB Knife Jr 2 ([Video 1]).
Abstract 12543: Glucagon-Like Peptide-1 Improves Endothelial and HDL Function Immediately after Roux-en-Y Gastric Bypass Prior to Body Weight Loss
Authors: Petia Doytcheva, Elena Osto, Caroline Corteville, Marco Bueter, Lucia Rohrer, Ulf Landmesser, Christian M Matter, Thomas A Lutz, Thomas F Luscher
Journal: Circulation (2013)

Background: Roux-en-Y gastric bypass (RYGB) reduces weight and long-term cardiovascular (CV) risk in obese patients. Glucagon-like peptide-1 (GLP-1) levels increase after RYGB and seem to mediate s...
Enhancer Hijacking of <i>BCL11B</i> Defines a Subtype of Lineage Ambiguous Acute Leukemia
Authors: Lindsey Montefiori, Sonja Seliger, Zhaohui Gu, Xiaotu Ma, Beisi Xu, Xiaolong Chen, Kirsten Dickerson, Tamara Westover, Anna Stengel, Ilaria Iacobucci, Shunsuke Kimura, Chunxu Qu, Jing Ma, Marc Valentine, Wolfgang Kern, Torsten Haferlach, Gang Wu, Jeffery M. Klco, Claudia Haferlach, Charles G Mullighan
Journal: Blood (2020)
Abstract 14259: Eosinophilic Granulomatosis Presenting as Non-ST Segment Elevation Myocardial Infarction
Authors: Karsh Gaurav, Vinayak Shenoy, Perry Fisher, Jordan Steinberg, Todd Anderson, Akshai Bhandary
Journal: Circulation (2020)

Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis characterized by small to medium size vessel vasculitis. Here, we present a case of newly diagnosed EGPA presenting as non-ST segment elevation myocardial infarction (NSTEMI). Case: A 53-year-old male with a history of asthma and nasal polyps presented with acute onset anginal chest pain, rising troponin T and CKMB without ischemic changes on electrocardiogram. He was admitted for NSTEMI. Cardiac catheterization showed non-obstructive coronary artery disease (Figure 1). Given his past medical history along with eosinophilia and pulmonary opacities seen on CT chest, there was concern for EGPA. Lung wedge resection biopsy showed parenchymal eosinophilia, granulomatous inflammation, and vasculitis that confirmed the diagnosis (Figure 2). Figure 1 Figure 2 Discussion: Cardiac involvement is known to be a major contributor to disease-related death, totaling up to 50% of cases, and therefore poses an important aspect of this rare disease. Recent reports, particularly concerning clinical differences given ANCA status, have shown that these patients might represent a heterogeneous group. For instance, ANCA-negative patients, such as our patient, more frequently develop heart conditions. We cultivate such discussion not only to bring attention to EGPA as an uncommon entity to the practice of many cardiologists, but also to point out that early recognition of cardiac involvement could reduce morbidity and mortality.
Association Between Early Severe Cardiovascular Events and Ustekinumab Treatment?—Reply
Authors: Florence Poizeau, Emmanuel Nowak, Alain Dupuy
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Chest ultrasonography by frontline physicians is more sensitive than CXR for diagnosing pneumothorax in trauma patients
Authors: Gregory Hall
Journal: Annals of Internal Medicine (2020)

Chan KK, Joo DA, McRae AD, et al. Chest ultrasonography versus supine chest radiography for diagnosis of pneumothorax in trauma patients in the emergency department. Cochrane Database Syst Rev. 2020;7:CD013031. 32702777.
Abstract 15066: Cost Comparison of Handmade versus Commercially Available Grafts Used for Pediatric Right Ventricular Outflow Tract Reconstruction
Authors: Maanasi S Mistry, Shawn C WEST, MELITA VIEGAS, mario castro medina, Victor O Morell
Journal: Circulation (2020)

Introduction: Handmade polytetrafluoroethylene (PTFE) conduits have similar durability and efficacy compared to commercially available conduits and homografts used for pulmonary valve replacement (PVR) in pediatric right ventricular outflow tract (RVOT) reconstruction. We evaluated the costs related to use of the PTFE conduits compared to commercial grafts. Hypothesis: When compared to commercial grafts in first-time RVOT reconstruction, PTFE conduits have reduced surgical day costs with similar overall hospital costs per day of conduit life. Methods: Data was collected via retrospective chart review of patients &lt; 2 years of age who underwent first-time PVR from 1/2010 - 3/2019. Initial procedure, all day-of-surgery, and subsequent reintervention costs and charges were examined. Patients were followed until conduit explant, patient death, or 3/2020 (whichever came first) and were adjusted to 2020 USD. Results: Of 52 instances of PVR in RVOT reconstruction, 36 (69%) of grafts were PTFE, and 16 (31%) were commercial. There were no statistically significant differences in gestational age; birth weight; weight, height, or age at intervention; hospital or intensive care unit length of stay; conduit life; or bypass, cross-clamp, or intubation duration between the groups. Compared to commercial grafts, PTFE conduits were associated with lower day-of-surgery hospital charge, day-of-surgery estimated cost, and graft/conduit charge. There was a trend toward lower aggregate cost over conduit life (Table). Aggregate cost per day of conduit life was similar between groups ( p = 0.26). Conclusions: In first-time PVR, PTFE conduits have lower initial and reintervention costs compared to commercially available conduits and homografts. In centers with expertise in handmade conduits, these may provide a less expensive alternative to commercial grafts in pediatric patients requiring RVOT reconstruction.
Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/07
Authors: Renato Bassan, Chiara Pavoni, Tamara Intermesoli, Orietta Spinelli, Manuela Tosi, Ernesta Audisio, Filippo Marmont, Chiara Cattaneo, Erika Borlenghi, Sergio Cortelazzo, Irene Cavattoni, Monica Fumagalli, Daniele Mattei, Claudio Romani, Agostino Cortelezzi, Nicola Fracchiolla, Fabio Ciceri, Massimo Bernardi, Anna Maria Scattolin, Lorella Depaoli, Arianna Masciulli, Elena Oldani, Alessandro Rambaldi
Journal: Blood Cancer Journal (2020)

Abstract An updated strategy combining pediatric-based chemotherapy with risk-oriented allogeneic hematopoietic cell transplantation (HCT) was evaluated in Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph− ALL) and compared with a published control series. Following induction–consolidation chemotherapy, responsive patients were assigned to receive maintenance chemotherapy or undergo early HCT according to the risk stratification criteria and minimal residual disease (MRD) status. Of the 203 study patients (median age 41 years, range 17–67), 140/161 with Ph− ALL achieved complete remission (86.9%; 91.6% ≤55 years, P = 0.0002), with complete MRD clearing in 68/109; 55 patients were assigned to maintenance chemotherapy, and 85 to HCT due to very high-risk characteristics (hyperleukocytosis, adverse genetics, early/mature T-precursor ALL, and MRD persistence). The 5-year relapse incidence was 36%, and the treatment-related mortality rate was 18%. Median overall and relapse-free survival were 7.4 and 6.2 years, with rates of 54 and 53% at 5 years, respectively, which were significantly better than those obtained with the historical protocol ( P = 0.001 and P = 0.005, respectively), without significant differences between maintenance and HCT cohorts. In prognostic analysis, MRD negativity and age ≤55 years were the most favorable independent prognostic factors. A reduction in treatment toxicity and further improvements in the risk definitions and risk-oriented design are the focuses of this ongoing research.
Abstract 14708: Temporal Relationship Between Erythropoietin Administration and Mitochondrial Dysfunction in Cardiac Ischemia/reperfusion Injury
Authors: Juthipong Benjanuwattra, Nattayaporn Apaijai, Titikorn Chunchai, Siriporn Chattipakorn, Busarin Arunsak, Nipon CHATTIPAKORN
Journal: Circulation (2020)

Introduction: Acute myocardial infarction remains a leading cause of mortality. Rapid restoration of coronary blood flow is the cornerstone of treatment. Paradoxically, it leads to a condition known as ischemia/reperfusion (I/R) injury which precipitates more injuries to the heart. Erythropoietin (EPO), a hormone produced by the kidneys in response to cellular hypoxia, reportedly provides cardioprotection following cardiac I/R injury in many preclinical experiments. Unfortunately, clinical trials failed to demonstrate cardioprotection when EPO was given after reperfusion. Therefore, we aim to determine the temporal influences on administering EPO in cardiac I/R injury. Hypothesis: Administration of EPO at different time points provides varying efficacy in reducing arrhythmias, LV and cardiac mitochondrial dysfunction after cardiac I/R injury. Methods: Male Wistar rats were divided into sham-operated and cardiac I/R group. In I/R group, rats were subdivided into 4 groups (n=10/group): vehicle, EPO pretreatment (P-EPO), EPO given during ischemia (I-EPO), and EPO given at reperfusion onset (R-EPO). EPO was intravenously given to the rats (5000 unit/kg). Rats underwent 30-min LAD ligation followed by 120-min reperfusion. Arrhythmia scores and LV function were recorded throughout the protocol. Then, rats were sacrificed to determine infarct size and mitochondrial function. Results: Cardiac I/R injury induced arrhythmias, LV and mitochondrial dysfunction (Fig . Administration of EPO before or during ischemia, but not at the onset of reperfusion, significantly attenuated LV dysfunction and infarct size. However, EPO did not reduce arrhythmia scores. Although EPO given at all time points reduced mitochondrial reactive oxygen species, EPO given at reperfusion failed to prevent mitochondrial swelling (Fig) . Conclusions: Acute EPO treatment before or during ischemia, but not at the onset of reperfusion, exerted cardioprotection against I/R injury.